ABBV vs CHE

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Chemed Corporation exhibits a stark divergence between its fundamental valuation and current market price, trading at a massive premium to its Graham Number ($171.6) and Intrinsic Value ($128.24). While the company maintains a stable Piotroski F-Score of 4/9 and an exceptionally low Debt/Equity ratio of 0.15, these health metrics are offset by negative YoY revenue and earnings growth. The combination of declining profitability, bearish insider activity from the CEO, and a valuation that is nearly 2.5x its defensive fair value suggests significant downside risk.